Free Trial

Immuneering (IMRX) Stock Price, News & Analysis

+0.01 (+0.65%)
(As of 05/22/2024 ET)
Today's Range
50-Day Range
52-Week Range
295,507 shs
Average Volume
306,481 shs
Market Capitalization
$45.96 million
P/E Ratio
Dividend Yield
Price Target

Immuneering MarketRank™ Stock Analysis

Analyst Rating
Moderate Buy
2.50 Rating Score
771.0% Upside
$13.50 Price Target
Short Interest
15.37% of Float Sold Short
Dividend Strength
News Sentiment
-0.17mentions of Immuneering in the last 14 days
Based on 3 Articles This Week
Insider Trading
Selling Shares
$3.05 M Sold Last Quarter
Proj. Earnings Growth
From ($2.03) to ($1.77) Per Share

Overall MarketRank

New Rank-Based ScoringMarketRank is calculated by averaging available category scores (with extra weight given to analysis and valuation), then ranking the company's weighted average against that of other companies.

3.40 out of 5 stars

Medical Sector

294th out of 919 stocks

Biotechnology Industry

7th out of 37 stocks

IMRX stock logo

About Immuneering Stock (NASDAQ:IMRX)

Immuneering Corporation, a clinical-stage oncology company, engages in the development of medicines for broad populations of cancer patients. Its lead product candidates include IMM-1-104, a dual-MEK inhibitor currently under Phase 1/2a clinical trial to treat patients with cancer, including pancreatic, melanoma, colorectal, and non-small cell lung cancer caused by mutations of RAS and/or RAF; and IMM-6-415 is in Investigational New Drug application to treat solid tumors. Immuneering Corporation was incorporated in 2008 and is based in Cambridge, Massachusetts.

IMRX Stock Price History

IMRX Stock News Headlines

Immuneering Corp Class A IMRX
Immuneering Recognizes Melanoma Awareness Month
Immuneering CEO acquires $55.3k in company stock
Immuneering Director Acquires 7.5% More Stock
See More Headlines
Receive IMRX Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Immuneering and its competitors with MarketBeat's FREE daily newsletter.

Company Calendar

Last Earnings
Next Earnings (Estimated)
Fiscal Year End

Industry, Sector and Symbol

Pharmaceutical preparations
Current Symbol
Year Founded

Price Target and Rating

Average Stock Price Target
High Stock Price Target
Low Stock Price Target
Potential Upside/Downside
Consensus Rating
Moderate Buy
Rating Score (0-4)
Research Coverage
8 Analysts


Net Income
Pretax Margin


Sales & Book Value

Annual Sales
Book Value
$2.65 per share


Free Float
Market Cap
$45.96 million
Not Optionable
12 Stocks Corporate Insiders are Abandoning Cover

If a company's CEO, COO, and CFO were all selling shares of their stock, would you want to know?

Get This Free Report

Key Executives

  • Dr. Benjamin J. Zeskind M.B.A. (Age 41)
    Ph.D., Co-Founder, President, CEO & Director
    Comp: $935.09k
  • Mr. Robert J. Carpenter M.B.A. (Age 78)
    M.S., Co-Founder & Chair Emeritus
    Comp: $75.36k
  • Dr. Brett M. Hall Ph.D. (Age 55)
    Chief Scientific Officer
    Comp: $905.41k
  • Mr. Harold E. Brakewood (Age 58)
    Chief Business Officer
    Comp: $579.77k
  • Ms. Mallory Morales CPA (Age 40)
    Principal Financial & Accounting Officer, Chief Accounting Officer and Treasurer
  • Ms. Paula George CPA
    Director of Accounting & Operations and Assistant Corporate Controller
  • Mr. Michael D. Bookman J.D. (Age 37)
    Chief Legal Officer & Secretary
  • Ms. Leah R. Neufeld (Age 51)
    Chief People Officer
  • Dr. Peter King Ph.D.
    Head of Discovery & VP
  • Dr. Praveen Nair Ph.D.
    Head of Translational Pharmacology & VP

IMRX Stock Analysis - Frequently Asked Questions

Should I buy or sell Immuneering stock right now?

8 Wall Street research analysts have issued "buy," "hold," and "sell" ratings for Immuneering in the last twelve months. There are currently 4 hold ratings and 4 buy ratings for the stock. The consensus among Wall Street research analysts is that investors should "moderate buy" IMRX shares.
View IMRX analyst ratings
or view top-rated stocks.

What is Immuneering's stock price target for 2024?

8 Wall Street analysts have issued 1-year price objectives for Immuneering's stock. Their IMRX share price targets range from $3.00 to $25.00. On average, they anticipate the company's share price to reach $13.50 in the next twelve months. This suggests a possible upside of 771.0% from the stock's current price.
View analysts price targets for IMRX
or view top-rated stocks among Wall Street analysts.

How have IMRX shares performed in 2024?

Immuneering's stock was trading at $7.35 on January 1st, 2024. Since then, IMRX shares have decreased by 78.9% and is now trading at $1.55.
View the best growth stocks for 2024 here

When is Immuneering's next earnings date?

The company is scheduled to release its next quarterly earnings announcement on Thursday, August 1st 2024.
View our IMRX earnings forecast

How were Immuneering's earnings last quarter?

Immuneering Co. (NASDAQ:IMRX) released its quarterly earnings data on Friday, March, 1st. The company reported ($0.52) EPS for the quarter, missing analysts' consensus estimates of ($0.46) by $0.06.

When did Immuneering IPO?

Immuneering (IMRX) raised $105 million in an IPO on Friday, July 30th 2021. The company issued 7,000,000 shares at a price of $14.00-$16.00 per share. Morgan Stanley, Jefferies, Cowen and Guggenheim Securities served as the underwriters for the IPO.

Who are Immuneering's major shareholders?

Immuneering's stock is owned by many different institutional and retail investors. Top institutional investors include Vanguard Group Inc. (4.06%) and Price T Rowe Associates Inc. MD (3.07%). Insiders that own company stock include Ann E Berman, Benjamin J Zeskind, Biren Amin, Brett Matthew Hall, Cormorant Asset Management, Lp, Harold Eugene Brakewood, Laurie Keating, Leah R Neufeld, Mallory Morales, Michael Bookman, Peter Feinberg and Scott Barrett.
View institutional ownership trends

How do I buy shares of Immuneering?

Shares of IMRX stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services.
Compare Top Brokerages Here.

This page (NASDAQ:IMRX) was last updated on 5/23/2024 by Staff

From Our Partners